(Circulation. 1999;100:594-598.)
© 1999 American Heart Association, Inc.
Clinical Investigation and Reports |
Stimulation of Fecal Steroid Excretion After Infusion of Recombinant Proapolipoprotein A-I
Potential Reverse Cholesterol Transport in Humans
From the Center for Metabolism and Endocrinology, Department of Medicine, and the Center for Nutrition and Toxicology, Novum, Karolinska Institute at Huddinge University Hospital, Huddinge (M.E., B.A.); King Gustaf V Research Institute, Karolinska Hospital, Stockholm (L.A.C.); and the Department of Medicine, University of Helsinki (T.A.M.).
Correspondence to Dr Bo Angelin, CME M63, Huddinge University Hospital, S-141 86 Huddinge, Sweden. E-mail bo.angelin{at}medhs.ki.se
Background—Apolipoprotein (apo) A-I is the major protein component of HDL, a cholesterol transport particle that protects against atherosclerosis. Apo A-I is believed to promote reverse cholesterol transport, transferring cholesterol from peripheral cells to the liver for subsequent elimination. To test this hypothesis in humans, we measured fecal steroid excretion before and after the intravenous infusion of human proapo A-I (precursor of apo A-I) liposome complexes.
Methods and Results—Four subjects with heterozygous familial
hypercholesterolemia were studied under
standardized conditions. The fecal excretion of bile acids and neutral
sterols was determined for 9 days before and 9 days after an
intravenous infusion of recombinant human proapo A-I (4 g
protein) liposome complexes. Plasma apoA-I and HDL
cholesterol levels increased transiently (mean peak
concentrations were 64% and 35% above baseline, respectively) during
the first 24 hours. Mean lipoprotein lipid and apolipoprotein levels
were not different during the 2 collecting periods, however. Serum
lathosterol, a precursor of cholesterol whose concentration
reflects the rate of cholesterol synthesis in vivo, was
also unchanged. The fecal excretion of cholesterol (neutral
sterols and bile acids) increased in all subjects (mean increase, +39%
and +30%, respectively), corresponding to the removal of 
500 mg/d
excess cholesterol after infusion. Control infusions with
only liposomes in 2 of the patients did not influence lipoprotein
pattern or cholesterol excretion.
Conclusions—Infusion of proapoA-I liposomes in humans promotes net cholesterol excretion from the body, implying a stimulation of reverse cholesterol transport. This mechanism may prove useful in the treatment of atherosclerosis.
Key Words: apolipoproteins • atherosclerosis • cholesterol • lipoproteins • metabolism
This article has been cited by other articles:
 |
|
 |
|
  F. M. Sacks, L. L. Rudel, A. Conner, H. Akeefe, G. Kostner, T. Baki, G. Rothblat, M. de la Llera-Moya, B. Asztalos, T. Perlman, et al. Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo J. Lipid Res., May 1, 2009; 50(5): 894 - 907. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Rader, E. T. Alexander, G. L. Weibel, J. Billheimer, and G. H. Rothblat The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis J. Lipid Res., April 1, 2009; 50(Supplement): S189 - S194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. deGoma, R. L. deGoma, and D. J. Rader Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J. Am. Coll. Cardiol., June 10, 2008; 51(23): 2199 - 2211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Wool, C. A. Reardon, and G. S. Getz Apolipoprotein A-I mimetic peptide helix number and helix linker influence potentially anti-atherogenic properties J. Lipid Res., June 1, 2008; 49(6): 1268 - 1283. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Morehouse, E. D. Sugarman, P.-A. Bourassa, T. M. Sand, F. Zimetti, F. Gao, G. H. Rothblat, and A. J. Milici Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits J. Lipid Res., June 1, 2007; 48(6): 1263 - 1272. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Thaveeratitham, W. Plengpanich, W. Naen-Udorn, S. Patumraj, and W. Khovidhunkit Effects of human apolipoprotein A-I on endotoxin-induced leukocyte adhesion on endothelial cells in vivo and on the growth of Escherichia coli in vitro Innate Immunity, February 1, 2007; 13(1): 58 - 64. [Abstract] [PDF]
|
|
|
|
 |
|
 C. R. Sirtori HDL and the progression of atherosclerosis: new insights Eur. Heart J. Suppl., October 1, 2006; 8(suppl_F): F4 - F9. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cuchel and D. J. Rader Macrophage Reverse Cholesterol Transport: Key to the Regression of Atherosclerosis? Circulation, May 30, 2006; 113(21): 2548 - 2555. [Full Text] [PDF]
|
|
|
|
 |
|
 A. H.E.M. Klerkx, K. E. Harchaoui, W. A. van der Steeg, S. M. Boekholdt, E. S.G. Stroes, J. J.P. Kastelein, and J. A. Kuivenhoven Cholesteryl Ester Transfer Protein (CETP) Inhibition Beyond Raising High-Density Lipoprotein Cholesterol Levels: Pathways by Which Modulation of CETP Activity May Alter Atherogenesis Arterioscler. Thromb. Vasc. Biol., April 1, 2006; 26(4): 706 - 715. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Duffy and D. J. Rader Emerging Therapies Targeting High-Density Lipoprotein Metabolism and Reverse Cholesterol Transport Circulation, February 28, 2006; 113(8): 1140 - 1150. [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Mooradian, M. J. Haas, and N. C. W. Wong The Effect of Select Nutrients on Serum High-Density Lipoprotein Cholesterol and Apolipoprotein A-I Levels Endocr. Rev., February 1, 2006; 27(1): 2 - 16. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Lamon-Fava, B. Postfai, M. Diffenderfer, C. DeLuca, J. O'Connor Jr, F. K. Welty, G. G. Dolnikowski, P. H. R. Barrett, and E. J. Schaefer Role of the Estrogen and Progestin in Hormonal Replacement Therapy on Apolipoprotein A-I Kinetics in Postmenopausal Women Arterioscler. Thromb. Vasc. Biol., February 1, 2006; 26(2): 385 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ohashi, H. Mu, X. Wang, Q. Yao, and C. Chen Reverse cholesterol transport and cholesterol efflux in atherosclerosis QJM, December 1, 2005; 98(12): 845 - 856. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Williams and I. Tabas Lipoprotein Retention--and Clues for Atheroma Regression Arterioscler. Thromb. Vasc. Biol., August 1, 2005; 25(8): 1536 - 1540. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Brousseau, M. R. Diffenderfer, J. S. Millar, C. Nartsupha, B. F. Asztalos, F. K. Welty, M. L. Wolfe, M. Rudling, I. Bjorkhem, B. Angelin, et al. Effects of Cholesteryl Ester Transfer Protein Inhibition on High-Density Lipoprotein Subspecies, Apolipoprotein A-I Metabolism, and Fecal Sterol Excretion Arterioscler. Thromb. Vasc. Biol., May 1, 2005; 25(5): 1057 - 1064. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. F. Asztalos, L. A. Cupples, S. Demissie, K. V. Horvath, C. E. Cox, M. C. Batista, and E. J. Schaefer High-Density Lipoprotein Subpopulation Profile and Coronary Heart Disease Prevalence in Male Participants of the Framingham Offspring Study Arterioscler. Thromb. Vasc. Biol., November 1, 2004; 24(11): 2181 - 2187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. B. Brewer Jr, A. T. Remaley, E. B. Neufeld, F. Basso, and C. Joyce Regulation of Plasma High-Density Lipoprotein Levels by the ABCA1 Transporter and the Emerging Role of High-Density Lipoprotein in the Treatment of Cardiovascular Disease Arterioscler. Thromb. Vasc. Biol., October 1, 2004; 24(10): 1755 - 1760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Mooradian, M. J. Haas, and N. C.W. Wong Transcriptional Control of Apolipoprotein A-I Gene Expression in Diabetes Diabetes, March 1, 2004; 53(3): 513 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Rader High-Density Lipoproteins as an Emerging Therapeutic Target for Atherosclerosis JAMA, November 5, 2003; 290(17): 2322 - 2324. [Full Text] [PDF]
|
|
|
|
|
|
J. W. Burgess, J. Boucher, T. A-M. Neville, P. Rouillard, C. Stamler, S. Zachariah, and D. L. Sparks Phosphatidylinositol promotes cholesterol transport and excretion J. Lipid Res., July 1, 2003; 44(7): 1355 - 1363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Post, R. de Crom, R. van Haperen, A. van Tol, and H. M.G. Princen Increased Fecal Bile Acid Excretion in Transgenic Mice With Elevated Expression of Human Phospholipid Transfer Protein Arterioscler. Thromb. Vasc. Biol., May 1, 2003; 23(5): 892 - 897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Sniderman, Z. Zhang, J. Genest, and K. Cianflone Effects on apoB-100 secretion and bile acid synthesis by redirecting cholesterol efflux from HepG2 cells J. Lipid Res., March 1, 2003; 44(3): 527 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Forrester Prevention of Plaque Rupture: A New Paradigm of Therapy Ann Intern Med, November 19, 2002; 137(10): 823 - 833. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Chiesa, E. Monteggia, M. Marchesi, P. Lorenzon, M. Laucello, V. Lorusso, C. Di Mario, E. Karvouni, R. S. Newton, C. L. Bisgaier, et al. Recombinant Apolipoprotein A-IMilano Infusion Into Rabbit Carotid Artery Rapidly Removes Lipid From Fatty Streaks Circ. Res., May 17, 2002; 90(9): 974 - 980. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. K. Shah, S. Kaul, J. Nilsson, and B. Cercek Exploiting the Vascular Protective Effects of High-Density Lipoprotein and its Apolipoproteins: An Idea Whose Time for Testing Is Coming, Part II Circulation, November 13, 2001; 104(20): 2498 - 2502. [Full Text] [PDF]
|
|
|
|
|
|
M. N. Nanjee, C. J. Cooke, R. Garvin, F. Semeria, G. Lewis, W. L. Olszewski, and N. E. Miller Intravenous apoA-I/lecithin discs increase pre-{beta}-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans J. Lipid Res., October 1, 2001; 42(10): 1586 - 1593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. K. Shah, J. Yano, O. Reyes, K.-Y. Chyu, S. Kaul, C. L. Bisgaier, S. Drake, and B. Cercek High-Dose Recombinant Apolipoprotein A-IMilano Mobilizes Tissue Cholesterol and Rapidly Reduces Plaque Lipid and Macrophage Content in Apolipoprotein E-Deficient Mice : Potential Implications for Acute Plaque Stabilization Circulation, June 26, 2001; 103(25): 3047 - 3050. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. von Eckardstein, J.-R. Nofer, and G. Assmann High Density Lipoproteins and Arteriosclerosis : Role of Cholesterol Efflux and Reverse Cholesterol Transport Arterioscler. Thromb. Vasc. Biol., January 1, 2001; 21(1): 13 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. K. Spady Reverse Cholesterol Transport and Atherosclerosis Regression Circulation, August 10, 1999; 100(6): 576 - 578. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Alam, R. S. Meidell, and D. K. Spady Effect of Up-regulating Individual Steps in the Reverse Cholesterol Transport Pathway on Reverse Cholesterol Transport in Normolipidemic Mice J. Biol. Chem., May 4, 2001; 276(19): 15641 - 15649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E. Spieker, I. Sudano, D. Hurlimann, P. G. Lerch, M. G. Lang, C. Binggeli, R. Corti, F. Ruschitzka, T. F. Luscher, and G. Noll High-Density Lipoprotein Restores Endothelial Function in Hypercholesterolemic Men Circulation, March 26, 2002; 105(12): 1399 - 1402. [Abstract] [Full Text] [PDF]
|
|